Current Opinion in Pharmacology (COP)

Current Opinion in Pharmacology is a well‑established, bimonthly review journal first published in 2001 and hosted on Elsevier’s ScienceDirect platform. It offers concise, high‑value review articles written by international experts that summarize and interpret significant recent research across all areas of pharmacology and drug discovery. Unlike primary research journals, it prioritizes interpretive commentary on recent findings — helping readers quickly grasp which advances are most impactful and why they matter. Coverage spans major biological systems including cardiovascular, endocrine, nervous, immune and musculoskeletal systems, as well as therapeutic areas such as cancer pharmacology, metabolic disorders, immunomodulation, anti‑infectives, neurological and psychiatric disorders and emerging technologies in pharmacological science. The journal’s reviews are typically invited by section editors — respected leaders in specialist areas — ensuring that each article reflects both depth of expertise and relevance to current scientific and clinical questions. Current Opinion in Pharmacology supports both subscription and hybrid open access publishing options, broadening its accessibility. Its content serves researchers, clinicians, students and professionals seeking authoritative perspectives on evolving pharmacological knowledge and trends in drug development and therapeutic innovation.

Current Opinion in Pharmacology (COP) is :-

• International, Peer-Reviewed, Open Access, Refereed, Drug Discovery, Pharmacology, drug discovery, systems pharmacology, therapeutic innovations, disease‑related pharmacology, clinical pharmacology, toxicology and emerging technologies , Online or Print , Bi-Monthly Journal

• UGC Approved, ISSN Approved: P-ISSN P-ISSN: 1471-4892, E-ISSN: 1471-4973, Established: 2001, Impact Factor: 4.2
• Does Not Provide Crossref DOI

• Not indexed in Scopus, WoS, DOAJ, PubMed, UGC CARE